News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Predictors for Mortality in ACTIVE-W Trial Identified
August 17, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MedWire News -- Disabling strokes and severe bleeds are each associated with an increased risk for mortality in patients receiving antithrombotic therapy for atrial fibrillation (AF), a new analysis of the ACTIVE-W trial suggests.
Twitter
LinkedIn
Facebook
Email
Print